Cardiovascular disease and smoking cessation

East MidlandsCardiovascular
Published Date: 1 Jul 2015

Concurrent treatment with metformin reduces the higher cardiovascular and mortality risk in ex- and current smokers in people with T2DM

Who needs to know?

Primary Care, Diabetes and Cardiology Specialist Teams

What have we found?

Our findings suggests that, in people with Type 2 diabetes, concurrent treatment with metformin attenuates the observed higher cardiovascular and mortality risk in ex- and current smokers. In addition to smoking cessation support, treatment with metformin, particularly in ex- and current smokers, should be encouraged.

Download